Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy

Cui Jiang(Liaoning Cancer Hospital & Institute), Tao Sun(Wuhan University), Lei Jiang(Second Military Medical University), Zhichao Gao(Liaoning Cancer Hospital & Institute), Na Li(Educational Department of Liaoning Province), Xiaorui Li(Liaoning Cancer Hospital & Institute), Shuo Wu(Hainan University), Yangyang Duan(Liaoning Cancer Hospital & Institute)
PeerJ
September 3, 2019
10.7717/peerj.7515
Cited by 18

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Genetics of rheumatoid arthritis contributes to biology and drug discovery
|Nature|2013|2.5k
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369
Autophagy Attenuates Diabetic Glomerular Damage through Protection of Hyperglycemia-Induced Podocyte Injury
|PLoS ONE|2013|230
Magnesium Levels in Drinking Water and Coronary Heart Disease Mortality Risk: A Meta-Analysis
|Nutrients|2016|100